1.410USD-2.76%Mkt Cap: 37.62M USDP/E: —Last update: 2026-05-26
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product cand…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap37.62M USD
Enterprise Value18.43M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-45.93M USD
Revenue/Share0.0000 USD
Last Price1.410 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.74
PEG—
EV/EBITDA—
EV/Revenue—
P/SInfinity
P/B1.95
EPS (TTM)-1.63
EPS (Forward)-0.53
52W Range
1.0903% of range11.64
52W High11.64 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-91866.00%
ROE-195.26%
ROA-141.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.58M USD
CapEx (TTM)1.04M USD
FCF Margin—
FCF Yield-29.90%
Net Debt-19.85M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio4.24
Quick Ratio4.11
Book Value/Sh0.7380 USD
Cash/Share0.8030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)7.000 USD
Target Range4.000 USD – 9.000 USD
# Analysts4
Ownership
Shares Out.26.59M
Float22.16M
Insiders11.16%
Institutions19.69%
Short Interest
Short Ratio12.6d
Short % Float14.99%
Short % Out.13.32%
Shares Short3.54M
Short (prev mo.)3.43M
Technical
SMA 501.344 (+4.9%)
SMA 2001.676 (-15.9%)
Beta1.05
S&P 52W Chg28.31%
Avg Vol (30d)396.46K
Avg Vol (10d)728.40K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—